



# SMEs in IMI2 Calls for Proposals

# Why should an SME participate in an IMI project?

- IMI projects are focused on **translating excellent research** into real world outcomes – an opportunity for SMEs
- Unique **collaborative partnerships** in pharmaceutical research and development
- Collaboration with large pharmaceutical companies allows **access to whole value chain** of drug discovery
- Build research and business networks
- Funding: **100%** of costs **reimbursed**


# Some examples of the leading role of SMEs in IMI projects

# IMIDIA delivers a world first – driven by SME involvement

- IMIDIA generated the first human pancreatic beta cell line
- A French SME was at the heart of the research

*‘Thanks to this collaboration, the robustness of our beta cells has been validated by large pharma companies – a major advantage for a biotechnology company like Endocells.’*

*– Anne-Fabienne Weitsch, CEO of Endocells*



# European Lead Factory

Target

Screening

Hit-to-lead

Lead-to-candidate

Preclinical

Phase I

Phase II

Phase III



EUROPEAN  
LEAD FACTORY

Advanced, ultra high throughput  
**screening facilities**

**500 000 screening compounds**  
from pharma & SMEs

Total Budget:	EUR 197 million
IMI funding:	EUR 80 million
SME funding:	<b>EUR 54 million</b>

*'The ELF provided the missing piece in the puzzle – a potent, selective compound that provides a strong starting point for further development towards the clinic'*

*– Dr. Margit Mahlapuu, ScandiCure*

# EBOMAN - Vaccine manufacture capability

Established a platform capable of rapidly producing sufficient quantities of the vaccine



*‘A great opportunity because we were part of an excellent network of experts (drug makers, manufacturers, etc) that goes beyond the financial support we received.*

*Our advice to other SMEs interested in applying to IMI is: Do it.’*

**Vibalogics**



# IMI IP rules consider SME's needs

- Opportunity for further development & validation of assets
- Background and sideground assets protected
- New results owned by the generator
- Result owner decides:
  - Best protection modalities
  - Exploitation strategy
- Access to expertise from the other partners on equal basis
- Publication/dissemination subject to conditions, such as respect of the legitimate interests

# SME participation in IMI2 Call 14



# Opportunities for SMEs in IMI2 Call 14

SMEs are particularly welcome to participate in IMI2 Call 14 topics in the following areas:

## **Topic 1: Targeted immune intervention for treatment of non-response and remission**

- Establishment of a bio-sample repository
- Generation and hosting of an integrated large scale data platform
- Specialty profiling of bio-samples, using state of the art and/or emerging technologies.
- Project management and administration capabilities including resources for project administration, management and communication.

# Opportunities for SMEs in IMI2 Call 14

## **Topic 2: Non-invasive clinical molecular imaging of immune cells**

- Imaging agents and technologies
- Advanced analytical approaches
- Data management practices

## **Topic 3: Development of a platform for federated and privacy-preserving machine learning in support of drug discovery**

- Hands-on expertise in solutions for big data handling at industrial scale, ICT security and information leakage aspects, high performance computing infrastructures, software engineering
- Machine learning technologies in the context of federated learning
- Deploying computational approaches in drug discovery and development
- General project management in the context of EU-funded projects

# Opportunities for SMEs in IMI2 Call 14

## Topic 4: Centre Of Excellence – Remote Decentralised Clinical Trials

- Experience on remote DCTs and deep expertise in Good Clinical Practice (GCP) using technology for recruiting and monitoring patients
- Telemedicine, medical technology companies with expertise in data validation, using approved medical devices for data capture in clinical trials and continuous monitoring.

# SME participation in ongoing IMI Projects

# IMI Drug Discovery Platforms - ELF




Screening deck of **500 000 compounds & ultra-HTS facilities** available **free** to anyone with an **innovative target to screen**.

Apply at <https://www.europeanleadfactory.eu>

Over **49 Hit Lists** already provided **free of charge** to European SMEs & academics

**Innovative compound library** ideas also welcome – rewards available

# IMI Drug Discovery Platforms - ENABLE



Drug discovery expertise available to take your **AMR lead project** all the way to **Phase 1 clinical trials**

Apply at <http://nd4bb-enable.eu/>

Support available to submit your proposal

**15 programmes** already selected



**Thank you**

[www.imi.europa.eu](http://www.imi.europa.eu)

 @IMI\_JU